You could forgive drug and biotech executives for having a bad case of target fixation.
After all, they do work in a field that is filled with time-consuming and expensive headaches.
Consider that the Biotechnology Innovation Organization (BIO), the world’s largest biotech trade organization, looked at 7,400 drug programs by 1,103 companies. They were investigating drug-approval rates.
The news was not good -just 9.6% of drugs scientists discover ever get approved for sale. That’s a one-in-ten shot.
With such daunting data, it’s no wonder that, even in a field already worth $1.2 trillion in global sales, industry leaders are on the lookout for ways to lower the cost of discovery and shorten time to market.
And with that goal in mind, I’ve uncovered a high-octane, large-cap firm that has become an essential ingredient in the drug sector’s success.
It’s a cloud-based leader in pharmaceutical efficiency that has a history of crushing the market by no small measure. It’s been doubling its earnings, on average, every 18 months…
As fears of overexposure to the China trade dispute in the microchip and semiconductor sectors are being proven wrong, the market rallies. Investors are realizing that the banned Chinese company, Huawei, is not as tightly woven into those sectors as it had feared, and strong demand for chips will be driven on by the pending rollout of 5G technology. This means that those entire sectors are currently undervalued. As the new 5G upgrade cycle promises to keep demand high for years to come, there’s one company in this sector whose sales are up 24% since the market rally, and whose earnings are doubling nearly every three years – meaning huge growth potential if you latch on now. Click here to watch.
If all you did was look at the headlines, you’d think this is a terrible time to invest in initial public offerings (IPOs).
Just take a look at this recent riff from Forbes, “Why WeWork Won’t Work! – Hello Neumann!,” or Bloomberg’s announcement, “Endeavor Makes Last-Minute Call to Yank IPO as Conditions Sour.” Big time financial news is clearly in love with the idea that anyone getting hyped up for a big name IPO is just setting themselves up for disappointment.
On paper, that narrative makes sense.
WeWork’s attempt at an IPO saw an optimistic estimated valuation of $47 billion falling to less than $14 billion before the offering was abandoned entirely. The loss was so devastating that the CEO resigned over it.
Not only that, but Peloton Interactive Inc. (PTON) dropped 11.2% in its first day of trading on Sept. 26, a decline which, according to The Wall Street Journal, directly influenced the decision of talent firm, The Endeavor Group, to also put off its own new stock debut out of fear of poor market conditions.
But what the media isn’t telling you is that tech and life sciences firms are still IPO leaders. That segment of the market is actually doing quite well overall.
Last week, I was in Las Vegas presenting at the first annual retreat of our sister operation, the National Institute for Cannabis Investors (NICI). While I was there, I realized just how many investors need to know what’s going on with the markets and the economy, and how they can be prepared for whatever chaos gets thrown at them.
The fact is, the S&P 500 was down on Oct. 2, up on Oct. 4, down on Oct. 8, and up again yesterday. The situation is crazier than ever.
That’s why it’s time to buckle up and learn the tools you’ll need to protect your profits in a sideways market.
The key to staying afloat will be your skills at portfolio management. Inparticular, you’ll need two of my favorite techniques that are perfect for times like these.